Evidentiary Standards for Diagnostics: When does a Biomarker become a Diagnostic for Cancer Treatment?

In both community and academic cancer centers there is a rapid adoption of NGS and other multiplex platforms to interrogate the biology of an individual’s tumor. For each individual patient, vast amounts of data are being generated, annotated with identification of “actionable” targets for therapeutic intervention. The level of evidence for these target-directed therapies ranges from […]